Heart Failure

Articles 1-16 of 444

Medical News
Aggressive loop diuretic therapy does not affect GDMT prescription rates after acute HF
In a PUSH-AHF substudy among hospitalized acute HF patients, the proportions of patients receiving GDMT at discharge and the achieved GDMT doses did not differ between the natriuresis-guided therapy and standard-care arms.
This summary is based on the publication of Voors AA, Damman K, Beldhuis IE, ...
10/04/2025
Medical News
Tirzepatide improves CV outcomes in obesity-related HFpEF, regardless of CKD
ACC.25 – In SUMMIT among patients with HFpEF and obesity, the treatment effect of tirzepatide on clinical outcomes was not modified by CKD.
 
This summary is based on the presentation of Milton Packer, MD (Dallas, TX, USA) at the ACC.25 Scientific Session - Tirzepatide In Patients With Heart Failure...
08/04/2025
Medical News
Consistent benefit of early TAVR in asymptomatic severe aortic stenosis, irrespective of NT-proBNP or hs-cTnT
ACC.25 – In the biomarker analysis from EARLY TAVR, the benefit of an early TAVR strategy on clinical outcomes was consistent regardless of baseline NT-proBNP and hs-cTnT levels in patients with asymptomatic, severe aortic stenosis.
This summary is based on the presentation of Brian Lindman, MD (Nas...
07/04/2025
Medical News
Elderly TAVI patients with aortic stenosis also benefit from dapagliflozin
ACC.25 – The DapaTAVI trial demonstrated dapagliflozin safely reduced the risk of all-cause mortality or HF worsening compared with standard care only in elderly with severe aortic stenosis undergoing TAVI who were at high risk of HF.
This summary is based on the presentation of Sergio Raposeiras-Ro...
02/04/2025
Medical News
Mixed results with mobile integrated health strategy in HF
ACC.25 – In the MIGHTy-Heart trial, a mobile integrated health strategy did not reduce 30-day hospital readmissions or improve health status in patients with HF compared with standard follow-up phone calls. However, the treatment effect was modified by age and sex.
This summary is based on the prese...
01/04/2025
Medical News
RCT on effect of fluid restriction on quality of life in chronic HF
ACC.25 – In FRESH-UP, restricting fluid intake to 1.5 L/day for 3 months did not affect the quality of life of chronic HF patients but did lead to more thirst distress than liberal fluid intake. There were no safety risks.
This summary is based on the presentation of Roland van Kimmenade, MD, PhD (N...
01/04/2025
Medical News
Neutral effect of intensive medical therapy in women with INOCA
ACC.25 – Among women with suspected INOCA, an intensive medical therapy strategy did not reduce the risk of MACE at 5 years compared with usual care.
 
This summary is based on the presentation of Eileen Handberg, PhD (Gainesville, FL, USA) at the ACC.25 Scientific Session - Primary And Secondary Ou...
30/03/2025
Medical News
Targeted proteomics improves CV risk prediction
A plasma protein-based risk model demonstrated superior performance compared to the PREVENT risk model in predicting cardiovascular outcomes among UK Biobank participants without CVD.
 
 
This summary is based on the publication of Ho FK, Mark PB, Lees JS et al. - A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia - Circulation. 2025 Feb 4;151(...
27/03/2025
Medical News
Comorbid AF does not influence effects of rapid GDMT uptitration in acute HF
A post-hoc STRONG-HF analysis showed rapid GDMT uptitration during and after hospitalization for acute HF was feasible and safe and improved clinical outcomes compared with usual care, regardless of a history of AF/atrial flutter.
 
This summary is based on the publication of Farmakis D, Davison B, Fountoulaki K, et al. - Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibr...
20/03/2025
Medical News
Finerenone’s effects in HFmrEF/HFpEF remain consistent regardless of obesity
Finerenone reduced CV death or worsening HF events compared with placebo in HFmrEF/HFpEF patients irrespective of baseline BMI, with possibly a greater effect in those with a higher BMI, as shown by a prespecified analysis of FINEARTS-HF.
 
This summary is based on the publication of Butt JH, Henderson AD, Jhund PS, et al. - Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of F...
12/03/2025
Medical News
Sex-specific lifetime risks of HFpEF and HFrEF in Europe
In a European population-based cohort study, the lifetime risk of incident HFrEF was higher in men, while women were at greater risk of developing HFpEF. Moreover, 8 modifiable risk factors substantially contributed to these risks, particularly in women.
 
This summary is based on the publication of Van Essen BJ, Emmens JE, Tromp J, et al. - Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years. Eur Heart J. 2024 Dec 30:eh...
06/03/2025
Medical News
Incremental benefits of GLP-1RA plus SGLT2i treatment in patients with HFpEF, T2D, and overweight/obesity
In a real-world retrospective cohort study among HFpEF patients with T2D and BMI ≥27 kg/m², adding GLP-1RAs to SGLT2 inhibitors was associated with lower risks of adverse outcomes, such as HF exacerbation, at 12 months compared with SGLT2 inhibitors only.
 
This summary is based on the publication of Patel R, Wadid M, Makwana B, et al. - GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors. JACC Heart...
24/02/2025
Medical News
Acoramidis approved in EU for treatment of ATTR-CM
Acoramidis has been approved in the EU for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
 
 
 
 
 
Acoramidis has been approved in the EU for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). The approval was based on positive results f...
17/02/2025
Medical News
Association between NT-proBNP and adverse outcomes in patients with HF and CKD
A pooled analysis of 4 large-scale RCTs among HFmrEF/HFpEF patients showed that for any given NT-proBNP concentration, the absolute risk of HF hospitalization or CV death was substantially higher in participants with lowest eGFR compared with those with preserved kidney function.
 
This summary is based on the publication of Neuen BL, Vaduganathan M, Claggett BL, et al. - Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fracti...
13/02/2025
Medical News
Impact of timing of worsening HF events and treatment effect of finerenone in HFmrEF/HFpEF
A secondary analysis of FINEARTS-HF in HFmrEF/HFpEF patients revealed those with recent HF worsening had a higher risk of CV death or total worsening HF events but also appeared to experience greater absolute benefit from finerenone compared with placebo.
 
This summary is based on the publication of Desai AS, Vaduganathan M, Claggett BL, et al. - Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol...
27/01/2025
Medical News
Outpatient worsening HF as prognostic marker in ATTR-CM
In a prespecified analysis of HELIOS-B, outpatient worsening HF was associated with increased mortality risk in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) but could be reduced by vutrisiran.
 
This summary is based on the publication of Fontana M, Maurer MS, Gillmore JD, et al. - Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-...
23/01/2025